Date Filed | Type | Description |
10/05/2023 |
3
| Conway Vikki L (See "Remarks") has filed a Form 3 on TEVA PHARMACEUTICAL INDUSTRIES LTD |
10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/28/2023 |
8-K
| Quarterly results |
08/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...
Docs:
|
"Deferred Prosecution Agreement",
"TEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ TEL AVIV, Israel & PARSIPPANY, N.J, August 21, 2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , has reached a deferred prosecution agreement with the U.S. Department of Justice to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will allow Teva to avoid mandatory exclusion from participation in U.S. federal health care programs, Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028. The Company has also agreed to donate $50 million worth of two generic products , to humanitarian organizations, and to divest one additional generic product to a third-party buyer. Teva admits in th..." |
|
08/10/2023 |
4
| Grant Angus (EVP, Business Development) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Granted 51,652 options to buy
@ $0 |
|
08/09/2023 |
4
| Kalif Eliyahu Sharon (EVP, CFO) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 35,125 shares
@ $9.7335, valued at
$341.9k
|
|
08/07/2023 |
4
| Weiss Amir (Chief Accounting Officer) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 1,981 shares
@ $9.921, valued at
$19.7k
|
|
08/07/2023 |
4/A
| Weiss Amir (Chief Accounting Officer) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD |
08/07/2023 |
4
| Vergis Janet S. (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| Satchi-Fainaro Ronit (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| Nisen Perry (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| MIGNONE ROBERTO (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| LIEBERMAN GERALD M (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| Elstein Amir (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| Crane Rosemary A (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 15,810 options to buy
@ $0 |
|
08/07/2023 |
4
| BARER SOL J (Director) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Exercised 28,162 options to buy
@ $0 |
|
08/03/2023 |
4
| Hughes Eric A (See "Remarks") has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 52,742 shares
@ $8.2987, valued at
$437.7k
Exercised 52,742 options to buy
@ $0 |
|
08/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/02/2023 |
8-K
| Quarterly results |
06/09/2023 |
SC 13G/A
| Capital Research Global Investors reports a 0% stake in Teva Pharmaceutical Industries Ltd. |
06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
05/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/24/2023 |
SD
| Form SD - Specialized disclosure report: |
05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/10/2023 |
8-K
| Quarterly results |
04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee",
"Opinion of Tulchinsky Marciano Cohen Levitski & Co. (Israeli law)",
"Opinion of Kirkland & Ellis LLP (New York law)",
"Opinion of Van Doorne N.V. (Dutch law)" |
|
03/08/2023 |
4
| Stark David Matthew (Exec. VP Chief Legal Officer) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 16,491 shares
@ $9.9309, valued at
$163.8k
Sold 49,475 shares
@ $9.4279, valued at
$466.4k
|
|
03/08/2023 |
4
| Drape Eric (Executive VP Global Operations) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 1,566 shares
@ $9.9309, valued at
$15.6k
Sold 4,699 shares
@ $9.4279, valued at
$44.3k
|
|
03/08/2023 |
4
| Dethlefs Sven (EVP, North America Commercial) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 19,355 shares
@ $9.9309, valued at
$192.2k
Sold 58,066 shares
@ $9.4279, valued at
$547.4k
|
|
03/08/2023 |
4
| Daniell Richard (Exec. VP, European Commercial) has filed a Form 4 on TEVA PHARMACEUTICAL INDUSTRIES LTD
Txns:
| Sold 18,002 shares
@ $9.9309, valued at
$178.8k
Sold 54,007 shares
@ $9.4279, valued at
$509.2k
|
|
|